October 2023 in “Journal of the American Academy of Dermatology” Clascoterone cream could be used for other skin conditions affected by hormones.
September 2024 in “Current Oncology” Docetaxel often causes hair loss, with limited effective treatments and no cure for permanent hair loss.
78 citations
,
October 2003 in “Cochrane library” Cyproterone acetate with estradiol may subjectively improve excessive hair growth in women, but it's not clinically better than other treatments.
March 2008 in “Aging health” Docetaxel is safe and works well for older people with cancer, with manageable side effects.
14 citations
,
August 2017 in “International Journal of Immunopathology and Pharmacology” Photodynamic therapy improved skin issues from sorafenib when other treatments failed.
April 2023 in “Research Square (Research Square)” A young woman had a rare, aggressive ovarian tumor that was hard to diagnose and treat, leading to disease progression despite treatment.
34 citations
,
July 1993 in “PubMed” 83 citations
,
October 2012 in “International Journal of Oncology” Wedelolactone selectively kills prostate cancer cells without harming normal cells.
2 citations
,
August 2019 in “Asian journal of pharmaceutical and clinical research” Cinnamon bark extract may help prevent weight loss and hair loss in breast cancer patients during chemotherapy and is safe to use.
October 2025 in “CRC Press eBooks”
March 2025 in “JAAD reviews.” Bicalutamide can reduce female pattern hair loss, especially in those with certain conditions, but has limited effects on other hair loss types.
April 2019 in “Journal of the Endocrine Society” Rapid virilization should be checked for possible ovarian or adrenal cancer.
26 citations
,
October 2019 in “JNCI Cancer Spectrum” Talazoparib is more effective than standard chemotherapy for advanced breast cancer with BRCA mutations.
1 citations
,
January 2022 in “Journal of Cancer Therapy” Ocoxin improves quality of life for advanced ovarian cancer patients on chemotherapy.
5 citations
,
August 2011 in “Journal of the American Academy of Dermatology” A patient's skin eruption was caused by the cancer drug cyclophosphamide and improved after stopping the drug.
February 2024 in “International Journal of Pharmaceutics” A new hair loss treatment combining minoxidil and cedrol improves hair growth and reduces side effects.
MVP treatment is effective and safe for recurrent breast cancer.
November 2013 in “Cancer” Oophorectomy reduces ovarian cancer risk for women with BRCA mutations, finasteride lowers prostate cancer risk without raising death risk, and prophylactic mastectomy rates are rising.
23 citations
,
October 2008 in “Journal of medicinal chemistry” PF-998425 is a new, effective, and non-phototoxic treatment for skin conditions related to androgens.
November 2008 in “Cancer Prevention Research” Chemoprevention can significantly lower cancer risks and needs more research and collaboration.
3 citations
,
April 1977 in “PubMed” The treatment improved acne, seborrhoea, and hirsutism, with some side effects like spotting and nervousness.
February 2026 in “Revista Eletrônica Polidisciplinar Voos.” A balanced approach using dutasteride and Serenoa repens can improve hair transplant success by protecting follicles and minimizing side effects.
January 2026 in “Journal of Ethnopharmacology” Cedrol promotes hair growth better than baricitinib by regulating immune cells.
1 citations
,
January 1998 in “International journal of cancer” Rubbing vitamin D3 on skin can help prevent hair loss from chemotherapy and slow breast tumor growth in mice.
65 citations
,
October 2008 in “Journal of Neuroendocrinology”
1 citations
,
March 1999 in “British journal of rheumatology” Adequate steroid treatment needed to limit bone loss in PMR patients.
522 citations
,
January 2001 in “Cancer investigation” Doxil is an effective, modified chemotherapy drug with a unique toxicity profile and shows promise in treating certain cancers.
October 2008 in “Clin-alert” Certain medications can reduce mortality risk in COPD patients, but others can increase risks of cardiovascular issues, postoperative delirium, and other adverse effects.
12 citations
,
March 2021 in “Patient Preference and Adherence” Patients and oncologists prioritize survival benefits, while payers focus on treatment costs.
4 citations
,
June 2024 in “Animals” Osaterone acetate reduces prostate size and enzyme levels in dogs with benign prostatic hyperplasia.